CORDIS
EU research results

CORDIS

English EN
The artificial pancreas in children aged 1 to 7 years with type 1 diabetes

The artificial pancreas in children aged 1 to 7 years with type 1 diabetes

Objective

TYPE 1 DIABETES is one of the most COMMON CHRONIC diseases in children with a RAPID increase in number of cases particularly in young children. Type 1 diabetes is associated with LIFE-LONG dependency on insulin administration. POOR glucose control leads to diabetes COMPLICATIONS, e.g. eye, heart, kidney disease, including BRAIN changes in young children. Episodes of VERY LOW glucose levels may be life threatening and are a major complication.

The ARTIFICIAL PANCREAS addresses the problem of LOW and HIGH glucose levels by delivering insulin BELOW and ABOVE pre-set amounts according to real-time sensor GLUCOSE levels, combining glucose SENSOR, insulin PUMP, and CONTROL ALGORITHM. The Artificial pancreas promises to TRANSFORM management of type 1 diabetes but EVIDENCE supporting its use during FREE LIVING in YOUNG CHILDREN is MISSING.

The project evaluates the biomedical, psychosocial, and cost effectiveness of NOVEL INDIVIDUALISED artificial pancreas in young children aged 1 to 7 years with type 1 diabetes. Following a PILOT (n=24), in the MAIN study (n=94) half of the participants (n=47) will be treated over 12 MONTHS by the ARTIFICIAL PANCREAS and the other half (n=47) by STATE-OF-THE-ART PREDICTIVE LOW GLUCOSE MANAGEMENT insulin pump therapy. Each treatment will last ONE YEAR. QUALITY OF LIFE will be assessed and semi-structured INTERVIEWS conducted to understand the impact on daily life. HEALTH TECHNOLOGY ASSESSMENT will support reimbursement.

The project will OPTIMISE artificial pancreas and SPEARHEAD SYSTEM-WIDE improvements in health care quality and health outcomes in YOUNG CHILDERN with TYPE 1 DIABETES who live with the disease LONGEST. By IMPROVING THERAPEUTIC OUTCOMES, the project will CHANGE clinical practice and INFLUENCE national and international treatment guidelines making the artificial pancreas WIDELY ACCEPTABLE as the state-of-art treatment modality in young children.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Address

Trinity Lane The Old Schools
Cb2 1tn Cambridge

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 567 828,75

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

MEDIZINISCHE UNIVERSITAT GRAZ

Austria

EU Contribution

€ 441 191,25

CENTRE HOSPITALIER DE LUXEMBOURG

Luxembourg

EU Contribution

€ 399 025

UNIVERSITAET LEIPZIG

Germany

EU Contribution

€ 399 025

MEDIZINISCHE UNIVERSITAT INNSBRUCK

Austria

EU Contribution

€ 399 025

THE LEEDS TEACHING HOSPITALS NATIONAL HEALTH SERVICE TRUST

United Kingdom

EU Contribution

€ 399 025

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 430 275

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 325 458,75

HEVA HEOR

France

EU Contribution

€ 93 780

JAEB CENTER FOR HEALTH RESEARCH FOUNDATION INC

United States

DIASEND AB

Sweden

EU Contribution

€ 182 843,75

Project information

Grant agreement ID: 731560

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    30 June 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 4 952 796,25

  • EU contribution

    € 4 637 477,50

Coordinated by:

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom